

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

Data Insights: Covid-2019 Monitor

Monday, February 22, 2021

The global scorecard



For more information contact us: Donald Luskin: 312 273 6766 <u>don@trendmacro.com</u>

Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2021 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

The US scorecard

| | | | | | | The te | n worst US | states | | | | | |
|--------------------------------------|------------|-------------|---------------|--------------------------|--|----------------------------|--|--------------|--------------|-----------------------|--|----------------|----------|
| New cases New Deaths New in hospital | | | | Quine cases Quine deaths | | | Qume in | hospital | Hospital use | ICU use | | | |
| CA | +6,760 | CA | +280 | TN | +5 | CA | 3,441,946 | CA | 49,105 | NY | 89,995 | AK 88% | DC 84% |
| NY | +6,610 | VA | + 134 | 00 | +3 | TX | 2,588,101 | TX | 41,343 | FL. | 78,946 | RI 86% | GA 84% |
| R_ | +4,935 | TX | + 130 | UT | +3 | FL | 1,834,708 | NY | 37,851 | NJ | 63,108 | GA 79% | AL 82% |
| TX | +4,484 | R. | +95 | R | +2 | NY | 1,578,785 | R_ | 30,434 | AZ | 56,946 | MA 79% | TX 82% |
| SC | +2,872 | NY | +75 | ND | +1 | L | 1,174,409 | PA | 23,597 | GA | 54,753 | CI 79% | DE 81% |
| NC | +2,541 | SC | +68 | AK | +0 | GA | 985,505 | NJ | 22,858 | OH | 49,372 | MD 78% | HL 80% |
| VA | +2,303 | OH | +67 | AS | +0 | CH DA | 953,767 | L | 22,466 | AL | 44,767 | SC 78% | MO 79% |
| NJ DA | +2,031 | IMA | +4/ | | +0 | PA | 913,497 | UH CA | 10,810 | | 42,445 | FL 78% | RI 79% |
| PA LA | +1,900 | IL INI | +40 | GU LI | +0 | | 842,037 907.067 | GA | 16,744 | | 34,439 | PA 77% | IVIS 19% |
| LA | + 1,009 | IIN | + 30 | п | +0 | A/L | 15 121 322 | IVII | 277 556 | VVI | 20,740 | LC 70% | UK 19% |
| | + 30,331 | | +912 | | T 14 | | 10,121,022 | | 211,000 | | 040,014 | | |
| All states | +58429 | | +1286 | | -2063 | All states | 27 879 604 | | 489.060 | | 856 143 | All states 71% | 71% |
| Topten | 62% | | 76% | | -1% | Topten | 54% | | 57% | | 63% | Median 71% | 69% |
| iop ton | 0270 | | 10/0 | | 170 | iop tori | 01/0 | | Sa | me states ni | ot reporting | | 0070 |
| | | | | | | Five mos | t improved l | JS states | 5 | | | | |
| Fewer da | aily cases | | | Fe | wer new de | aths | | Fewer n | ew hospita | lizations | | Most recoverie | s |
| R. | -2,194 | | | | CA | -48,545 | | | TX . | -167 | | TX | +5,748 |
| TX | -2,002 | | | | TX | -41,083 | | | MD | -109 | | СН | +2,735 |
| GA | -1,578 | | | | NY | -37,701 | | | PA | -100 | | SC | +1,512 |
| СН | -1,150 | | | | FL. | -30,244 | | | LA | -50 | | NM | +1,444 |
| NY | -1,082 | | | | PA | -23,543 | | | L | -38 | | TN | +1,335 |
| 350,000 - | | | | | | | | | | | | | - 7.0% |
| 000,000 | | | | | | | | | | | | | 1.070 |
| | | | | | | | | | | | | | |
| 300,000 - | Unit | ed Stat | tes | | | | As of Feb 21 | | | | | | - 6.0% |
| | 855.9 | 40 bp of pc | opulation in | fected … | la serie de la companya de | · | | | | | | | |
| 050.000 | 15.01 | 5 bp of por | pulation fata | alities | | | | | | | | | 5.000 |
| 250,000 - | 38.1 n | nedian pop | pulation age | | | A State | | | | | | n IAN | - 5.0% |
| aths | | | | | | $\sim 10^{-1}$ | 0 | | | , | - M | | |
| 8 모 200,000 - | | | | 1. | | 2-week fatality rate 1.76% | | | | | | | - 4.0% |
| es ar | | | | | | N. | Cume | fatality rat | e 1.75% — | $\langle \rangle$ | <u> </u> | W. L'IN | e fat |
| case | | | | | | | and the second s | | | | | | ality |
| 출 150,000 - | | | | | | | 27,879,604 | cases cun | nulative | | | | - 3.0% a |
| Daily | | | | | | | +58,429 | cases too | day | · · · · · · · · · · · | l l' | | |
| 100.000 | | | | | | | 489,0 | 60 deaths | cumulative | _ | Contra Co | | 2.0% |
| 100,000 - | | | | | | | +1 | ,286 death | ns today | | | N. | 2.0% |
| | | | \sim | | | | 1AA | | | ⊾N – | | | A |
| 50,000 - | | | 14 | | | AN AN | "Mm. | | MAN | Y | | <u> </u> | 1.0% |
| | | | 1 | MAA | A.A.A. - | N' | · • • | v ₩\V | WV V | | | | |
| | | | 8 | • | | V.v. | 7- | day moving a | verage cases | | | | |
| | 1 lan 79 | Foh 25 | Mar 24 | Δpr 21 | May 10 | lun 16 bil | 1 <u>4</u> Aug 11 | San Q | Oct 6 | Nov 3 | Dec 1 | Dec 29 lan 26 | ➡ 0.0% |
| 0000 | Jun 20 | 10020 | , mui 24 | NPIZI | 11109 10 | Juli 10 Juli | - Aug II | 00P 0 | 0010 | 1101 3 | D00 1 | 500 20 JUII 20 | |

Source: <u>Covid Tracking Project</u>, <u>Dept. of Health and Human Services</u>, <u>CDC</u>, TrendMacro calculations

Rolling out the vaccines in the US

AK 41.0% 20.8% 11.2%

HI 28.1% 15.5% 7.3%

| US overall Over last day 75:20 million doses distributed +0.23 million/day 43:63 million doses administered +0.80 million/day 43:63 million persons with one shot +0.80 million/day 18:87 million persons with two shots +0.97 million/day 652 million shots long-term care residents/staff +0.12 million/day 83:9% of distributed doses administered 55% 2 shots 100% of LTC 1 shot 45.9% 2 shots Medema as % population Middle Two shots received as % population Middle Worst 15.5% 16.7% 121.3% 2003% 24.3% 26.1% 22.8% 21.3% 2003% 24.3% 26.1% 22.8% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 13.4% 12.4% 15.5% 16.7% | <u> </u> | | | | | | | | | | | | | |
|---|-----------------|------------|---|-------------|---------------|-----------------|--------------|----------------|----------|-----------------------|-------------------|---------------|--|--|
| 75 20 million doses distributed +0.23 million/day 63 09 million doses administered +1.80 million/day 43 63 million persons with two shots +0.82 million/day 652 million spersons with two shots +0.97 million/day 652 million spersons with two shots +0.12 million/day 83.9% of distributed doses administered 10.12 million/day 13.1% of US pop 1 shot 5.6% 2 shots 100% of LTC 1 shot 45.9% 2 shots Modelma 40 today's dosing pace, agw as %, population Middle 0 for shot received as %, population Middle 14.7% 14.7% 13.3% of UD MT Norst Norst Windle Worst Windle 14.7% 13.4% 12.0% 24.3% 13.4% 12.4% 15.5% 15.7% 14.0% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% <tr< th=""><th>-</th><th colspan="8">US overall</th><th colspan="4">Over last day</th></tr<> | - | US overall | | | | | | | | Over last day | | | | |
| 63.09 million doses administered +1.80 million/day 43.63 million persons with two shots +0.82 million/day 18.87 million persons with two shots +0.97 million/day 6.52 million shots long-term care residents/staff +0.12 million/day 13.1% of US pop 1 shot 5.6% 2 shots 100% of LTC 1 shot 5.6% 2 shots At today's dosing pace, 49% 00 so fLTC 1 shot 5.6% 2 shots At today's dosing pace, 49% 00 so fLTC 1 shot 5.6% 2 shots At today's dosing pace, 49% 00 so fLTC 1 shot 15.5% 2 shots At today's dosing pace, 49% 00 so hots received 32.29 days by Jan 16, 2022 US will achieve herd immunity in 10 ms hots received 32.3% 8% population 7.2% 13.3% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.3% 13.2% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% 12.4% 13.4% | | | 75.20 million doses distributed | | | | | | | | +0.23 million/day | | | |
| 43.63 million persons with one shot +0.82 million/day 18.87 million persons with two shots +0.97 million/day 5.52 million shots long-term care residents/staff +0.12 million/day 83.9% of distributed doses administered 5.5% 2 shots 13.0% of US op 1 shot 5.5% 2 shots 5.52 million shots received 45.9% 2 shots 5.58 % 2 population Middle 0 ne shot received Middle 8 % population Middle WA ID MT 10 MT MN 21.3% 20.0% 24.4% 14.7% 13.4% 12.4% 13.4% 12.4% 13.3% 20.0% 24.3% 26.1% 22.4% 13.1% 13.4% 12.4% 12.3% 20.0% 24.4% 12.7% 13.3% 12.5% 13.4% 12.4% 13.3% 12.9% 20.0% 24.3% 21.1% 22.4% 13.1% 12.4% 13.3% 15.5% 16.7% 14.0% | | | 63.09 million doses administered | | | | | | | +1.80 million/day | | | | |
| 18.87 million persons with two shots +0.97 million/day 6.52 million shots long-term care residents/staff +0.12 million/day 83.9% of distributed doses administered 5.6% 2 shots 13.1% of US pop 1 shot 5.6% 2 shots 100% of LTC 1 shot 5.6% 2 shots At today's dosing pace, 43% 0.95 % population Middle 0.95 % population 12.3% 13.4% 12.4% 15.5% 16.7% 13.4% 12.4% 15.5% 16.7% 13.4% 12.4% 22.8% 13.4% 12.4% 13.3% 13.4% 12.4% 30.2% 13.4% 13.4% 12.4% 13. | | | 43.63 million persons with one shot | | | | | | | +0.82 million/day | | | | |
| 6.52 million shots long-term care residents/staff +0.12 million/day B3.9% of distributed doses administered 13.1% of US pop 1 shot 5.6% 2 shots 100% of LTC 1 shot 5.6% 2 shots Moderna State Moderna 49% Doses distributed Best 32.99 Clays State Middle Middle Two shots received Middle US will achieve herd immunity in 1.52 % population Worst 15.5% Wa D MT ND MN Viral 22.4% 14.7% 13.2% 1.34% 20.0% 24.3% 25.1% 12.2% 1.34% 12.4% 15.5% 16.7% 14.0% 1.34% 12.4% 15.5% 16.7% 22.4% 1.34% 12.4% 15.5% 16.7% 22.4% 1.34% 12.4% 15.5% 17.7% 12.2% 1.34% 12.4% 15.5% 17.7% 12.2% 1.34% 12.4% 15.5% 17.7% 12.2% <th></th> <th></th> <th colspan="7">18.87 million persons with two shots</th> <th colspan="4">+0.97 million/day</th> | | | 18.87 million persons with two shots | | | | | | | +0.97 million/day | | | | |
| Volume under volume volume Volume under volume volume volume Volume under volume volume volume volume State Doses distributed as % population Volume | | | 6.52 million shots long-term care residents/staff | | | | | | | +0.37 million/day | | | | |
| 13.1% of US pop 1 shot 5.5% 2 shots 100% of LTC 1 shot 5.6% 2 shots Network of LTC 1 shot State Network of LTC 1 shot Network of LTC 1 shot Network of LTC 1 shot State Network of LTC 1 shot Note the LTC 1 shot Network of LTC 1 shot Network of LTC 1 shot Note the LTC 1 shot Network of LTC 1 shot Network of LTC 1 shot Note the LTC 1 shot NI NI NI Note the LTC 1 shot Network of LTC 1 shot Network of LTC 1 shot Note the LT 1 shot NI NI | | | 83.9% of a | distributed | doses adm | inistered | | | | 10.12 1111 | ion, duy | | | |
| No. No. Or bor bor provide District Circle bord District Circle b | | | 13.1% of I | IS non 1 sł | not | | 5.6% 2 sh | ots | | | | | | |
| Visit and Weight State Mederna At today's dosing pace, a % population Mederna At today's dosing pace, a % population Pfter/BioNTech 51% Doses distributed as % population Best Middle Middle State | | | 100% of L | TC 1 shot | 101 | | 15 Q% 2 cm | hote | | | | | | |
| State At 10 duly s dusing pade, 49% And 29% Doses distributed as % population Best 329 g days Dres shot received as % population Middle Worst 1533 days Worst Worst Still achieve herd immunity in 1533 days 162022 US will achieve herd immunity in 134% To shot received as % population Worst 1553 days Will 21.3% 200% 24.3% 26.1% 22.8% 23.1% 22.8% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 12.2% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 12.2% 15.3% 0R NV WY SD IA IN 0H PA NJ CT RI 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.3% 20.6% 22.4% 23.4% 21.6% 23.2% 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.3% 5.3% | | | 100 /0 01 L | 10 1 3101 | | | | | | <mark>Hed</mark> erna | Pfizer/BioN | Tech | | |
| Werry American will have two in 329 days by Jan 16, 2022 US will achieve herd immunity in 153 days by Jul 23, 2021 ME 25.0% 14.2% 5.7% Widdle as % population Two shots received as % population Worst Middle Worst Mid US US US UI 22.4% 14.7% 6.2% VT NH 26.2% 24.2% 14.7% 6.2% NY VT NH 26.2% 24.2% 14.7% 6.0% NY NMA 21.4% 25.2% 6.0% NY MA 21.4% 25.2% 6.0% NY MA 21.4% 25.2% 12.2% NY MA 21.4% 22.8% 21.9% 23.4% NY 24.6% 27.6% 23.4% NY 21.8% 27.6% 23.4% NY 22.8% 24.0% 21.0% 23.4% NY 22.8% 24.0% 24.0% NY 25.6% 24.0% 24.0% 27.6% NY 25.6% 23.4% NY 24.6% 24.0% 27.6% NY 22.8% 24.0% 24.0% NY 22.8% 24.0% 23.4% NY 23.4% NY 23.4% NY 23.4% NY 25.6% 28.8% NY 28.8% NY 28.8% NY 28.8% NY 28.8% NY 28.8% NY 28.8% | | | | | | | At louay s | s uosing p | | 49% | 5 <mark>1%</mark> | | | |
| State Doses distributed as % population Best 3 % population Best Middle 3 % population Middle Two shots received as % population Middle 1 3 % population Worst Worst Middle 22.4% 14.2% 1 4.2% 5.7% 22.4% 14.7% 1 4.2% 5.7% 0 me shots received as % population Worst Will 22.4% 1 4.7% 13.2% 6.2% 7.2% 0 me shots received as % population Worst Will U Mid N 21.3% 20.0% 24.3% 26.1% 22.8% 23.1% 22.8% 21.4% 25.2% 6.0% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 12.2% 15.3% 5.4% 6.6% 8.6% 4.7% 5.8% 6.0% 5.3% 7.7% 7.6% 20.0% 22.5% 23.4% 21.6% 27.6% | | | | | | | every Am | erican will | nave two | In | | | | |
| Doses distributed as % population One shot received as % population Middle Two shots received as % population Morst 1533 Clays by Jul 23, 2021 VT NH 25.0% 24.2% 14.2% 5.7% YT NH 26.2% 24.3% 26.1% 22.8% 23.1% 22.8% 21.4% 25.2% 6.0% VA ID MT ND MN IL MI 22.8% 23.1% 22.8% 23.1% 22.8% 21.4% 25.2% 6.0% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.2% 15.3% 6.0% 5.3% 6.0% 5.3% 6.0% 5.3% 6.0% 5.3% 6.0% 5.3% 7.6% 5.2% 6.6% 8.6% 6.1% 4.4% 6.5% 6.0% 5.3% 7.6% 5.3% 7.6% 5.3% 7.6% 5.3% 7.6% 5.3% 7.6% 5.3% 7.6% 5.3% 7.6% 5.3% 7.6% 5.3% 7.6% 5.3% 7. | | | Sta | ate | | | 328 | 9 QS | IVS | | | | | |
| US will achieve herd immunity in One shot received as % population Two shots received as % population Middle Worst Wi 22.4% 14.7% 6.2% VI 22.4% 14.7% 6.2% VI 22.4% 14.7% 6.2% VI 22.4% 14.7% 6.2% VI 22.4% 14.7% 6.2% VI 22.4% 14.7% 6.2% VI 22.4% 14.7% 6.2% VI 22.4% 14.7% 6.2% VI 22.4% 12.2% VI 12.2% 5.3% VI 22.2% 6.0% WA D MT ND MN IL MI VY MA 21.4% 5.4% 5.5% 6.6% 8.6% 6.1% 4.4% 6.5% 6.0% 5.3% OR NV WY SD IA IN OH PA NJ CT RI 21.4% 52.6 6.6% 8.6% 6.1% 4.4% 6.5% 6.0% 5.3% 12.9% 31.4% 13.0% 12.2% 13.0% 12.2% 13.0% 12.2% 13.0% 12.9% 23.2% 23.2% 23.2% 23.2% 23.2% 23.2% 23.2% 23.2% 23.2% 23.2% 23.2% 23.2% 13.1% 13.7% | | | Doses di | stributed | Rect | by Jan 16, 2022 | | | | | | | | |
| One shot received as % population Middle Worst 1533 clays ME 25.0% 14.2% 5.7% With as % population Worst Image: Second Secon | as % population | | | | | | US will ac | hieve here | y in | | | | | |
| Locotical y S 25.0% 25.0% 14.2% 12.2% 14.2% 12.2% 14.2% 12.2% 12.2% 12.2% 12.2% 6.0% | | | One shot | received | Middle | Middle 152 dave | | | | | | ME | | |
| Worst Worst Image: Signal and S | | | as % po | pulation | | | | | iy S | | | 25.0% | | |
| WI WI VI VII VI | | | | s received | Worst | | by Jul 23 | , 2021 | | |] | 14.2% 5.7% | | |
| WA ID MT ND MN IL MI NV MA 21.3% 20.0% 24.3% 26.1% 22.8% 23.1% 22.8% 21.4% 25.2% 15.3% 6.0% 31.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 15.3% 6.0% 5.3% 5.2% 6.6% 8.0% 6.1% 4.4% 6.5% 6.0% 23.2% 15.3% 6.0% 23.2% 15.3% 6.0% 23.2% 15.3% 10.0% 5.3% 10.0% 5.3% 10.0% 5.3% 10.0% 12.2% 15.3% 10.2% 23.2% 23.4% 21.6% 27.6% 23.2% 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 13.2% 16.3% 12.9% 5.3% 16.3% 12.9% 23.2% 23.4% 25.0% 23.4% 24.0% 21.0% 12.9% 5.8% 12.9% 5.8% 12.9% 5.8% 12.9% 5.8% 12.9% 5.8% | | | uu 70 pu | pulation | | | WI | | | | VT | NH | | |
| IA.7% 14.7% 13.2% 6.2% 7.2% 6.0% WA ID MT ND MN IL MI 21.3% 20.0% 24.3% 26.1% 22.8% 23.1% 22.8% 21.4% 5.5% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 6.0% 5.3% 54% 5.2% 6.6% 8.6% 6.1% 4.4% 6.5% 6.0% 5.3% OR NV WY SD IA IN OH PA NJ CT RI 21.9% 21.0% 26.1% 30.2% 22.4% 22.1% 21.5% 23.4% 21.6% 27.6% 23.2% 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.2% 16.3% 12.9% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO | | | | | | | 22.4% | | | | 26.2% | 24.2% | | |
| WA ID MT ND MN IL MI 21.3% 20.0% 24.3% 26.1% 22.8% 23.1% 22.8% 21.4% 25.2% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 12.2% 15.3% 5.4% 5.2% 6.6% 8.6% 6.1% 4.4% 6.0% 5.3% OR NV WY SD IA IN OH PA NJ CT RI 21.9% 21.0% 26.1% 30.2% 22.4% 22.1% 21.5% 23.4% 21.6% 27.6% 23.2% 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.7% 13.0% 13.2% 16.3% 12.9% 6.3% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO NE MO KY WV VA MD | | | | | | | 14.7% | | | | 14.7% | 13.2% | | |
| WA ID M1 ND MIN IL MI IV MA 21.3% 20.0% 24.3% 26.1% 22.8% 23.1% 22.8% 21.4% 25.2% 13.4% 12.4% 15.5% 16.7% 14.0% 13.8% 12.7% 12.2% 15.3% 5.4% 5.2% 6.6% 8.6% 6.1% 4.4% 6.5% 6.0% 5.3% OR NV WY SD IA IN OH PA NJ CT RI 21.9% 21.0% 26.1% 30.2% 22.4% 22.1% 21.5% 23.4% 21.6% 23.6% 13.2% 16.3% 12.9% 6.3% 5.4% 6.8% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO NE MO KY WV VA MD DE 23.2% 20.5% 23.4% 25.0% 20.8% 22.5% 2 | r | 14/4 | | NAT | | NAN I | 6.2% | N 41 | 1 | NIX/ | 7.2% | 6.0% | | |
| 21.3 % 22.6 % 22.3 % 22.3 % 22.3 % 22.3 % 22.3 % 22.3 % 22.3 % 22.3 % 22.3 % 22.3 % 12.2 % 15.3 % 13.4 % 12.4 % 15.5 % 16.7 % 14.0 % 13.8 % 12.7 % 12.2 % 15.3 % 0 R NV WY SD IA IN OH PA NJ CT RI 21.9 % 21.0 % 26.1 % 30.2 % 22.4 % 22.1 % 21.5 % 23.4 % 21.6 % 23.2 % 13.1 % 13.0 % 15.5 % 17.7 % 14.1 % 13.0 % 12.7 % 13.0 % 13.2 % 16.3 % 12.9 % 6.3 % 5.4 % 6.8 % 8.6 % 4.7 % 5.8 % 5.6 % 4.9 % 5.7 % 7.6 % 5.8 % CA UT CO NE MO KY WV VA MD DE 23.2 % 20.5 % 23.4 % 25.0 % 20.8 % 22.5 % 26.9 % 22.8 % 24.0 % 21.0 % 13.7 % 11.1 % 13.0 % <td< th=""><th></th><th>21 2%</th><th>1D 20.0%</th><th>IVI I</th><th>ND 26.1%</th><th>1VIIN</th><th>IL 22.10/</th><th>1VII 22.00/</th><th></th><th>NY 21.4%</th><th>25.2%</th><th></th></td<> | | 21 2% | 1D 20.0% | IVI I | ND 26.1% | 1VIIN | IL 22.10/ | 1VII 22.00/ | | NY 21.4% | 25.2% | | | |
| 5.4% 5.2% 6.6% 8.6% 6.1% 4.4% 6.5% 6.0% 5.3% OR NV WY SD IA IN OH PA NJ CT Rl 21.9% 21.0% 26.1% 30.2% 22.4% 22.1% 21.5% 23.4% 21.6% 27.6% 23.2% 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.7% 13.0% 13.2% 16.3% 12.9% 6.3% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO NE MO KY WV VA MD DE 23.2% 20.5% 23.4% 25.0% 20.8% 22.5% 26.9% 22.8% 24.0% 21.0% 13.7% 11.1% 14.2% 13.0% 12.0% 13.7% 12.3% 13.7% 5.0% 4.6% 6.6% 6.1% 5.5 | ł | 13.4% | 12.0% | 15.5% | 16.7% | 14 N% | 13.8% | 12.0 % | | 12.4% | 15.3% | | | |
| OR NV WY SD IA IN OH PA NJ CT RI 21.9% 21.0% 26.1% 30.2% 22.4% 22.1% 21.5% 23.4% 21.6% 27.6% 23.2% 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.7% 13.0% 13.2% 16.3% 12.9% 6.3% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% 6.3% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO NE MO KY WV VA MD DE 23.2% 20.5% 23.4% 25.0% 20.8% 22.5% 26.9% 22.8% 24.0% 21.0% 13.7% 11.1% 14.2% 13.0% 12.0% 12.7% 16.2% 13.7% 13.7% 5.0% 4. | | 5.4% | 5.2% | 6.6% | 8.6% | 6.1% | 4.4% | 6.5% | | 6.0% | 5.3% | | | |
| 21.9% 21.0% 26.1% 30.2% 22.4% 22.1% 21.5% 23.4% 21.6% 27.6% 23.2% 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.7% 13.0% 13.2% 16.3% 12.9% 6.3% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO NE MO KY WV VA MD DE 23.2% 20.5% 23.4% 25.0% 20.8% 22.5% 26.9% 22.8% 24.0% 21.0% 13.7% 11.1% 14.2% 13.0% 12.0% 12.7% 16.2% 13.7% 12.3% 13.7% 5.0% 4.6% 6.6% 6.1% 5.5% 5.7% 9.7% 5.9% 5.7% 4.8% AZ NM KS AR TN NC SC DC 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% <th>ľ</th> <th>OR</th> <th>NV</th> <th>WY</th> <th>SD</th> <th>IA</th> <th>IN</th> <th>OH</th> <th>PA</th> <th>NJ</th> <th>СТ</th> <th>RI</th> | ľ | OR | NV | WY | SD | IA | IN | OH | PA | NJ | СТ | RI | | |
| 13.1% 13.0% 15.5% 17.7% 14.1% 13.0% 12.7% 13.0% 13.2% 16.3% 12.9% 6.3% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO NE MO KY WV VA MD DE 23.2% 20.5% 23.4% 25.0% 20.8% 22.5% 26.9% 22.8% 24.0% 21.0% 13.7% 11.1% 14.2% 13.0% 12.0% 12.7% 16.2% 13.7% 12.3% 13.7% 5.0% 4.6% 6.6% 6.1% 5.5% 5.7% 9.7% 5.9% 5.7% 4.8% 4.6% 6.6% 6.1% 5.5% 5.7% 9.7% 5.9% 5.7% 4.8% 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% < | | 21.9% | 21.0% | 26.1% | 30.2% | 22.4% | 22.1% | 21.5% | 23.4% | 21.6% | 27.6% | 23.2% | | |
| 6.3% 5.4% 6.8% 8.6% 4.7% 5.8% 5.6% 4.9% 5.7% 7.6% 5.8% CA UT CO NE MO KY WV VA MD DE 23.2% 20.5% 23.4% 25.0% 20.8% 22.5% 26.9% 22.8% 24.0% 21.0% 13.7% 11.1% 14.2% 13.0% 12.0% 12.7% 16.2% 13.7% 12.3% 13.7% 5.0% 4.6% 6.6% 6.1% 5.5% 5.7% 9.7% 5.9% 5.7% 4.8% AZ NM KS AR TN NC SC DC 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% 5.2% 6.6% 4.9% 7.5% OK LA MS AL GA 6.9% 6.5% 4.7% 4.5% 5.7% | | 13.1% | 13.0% | 15.5% | 17.7% | 14.1% | 13.0% | 12.7% | 13.0% | 13.2% | 16.3% | 12.9% | | |
| CA OT CO TRL IND RT WV VR IND DL 23.2% 20.5% 23.4% 25.0% 20.8% 22.5% 26.9% 22.8% 24.0% 21.0% 13.7% 11.1% 14.2% 13.0% 12.0% 12.7% 16.2% 13.7% 12.3% 13.7% 5.0% 4.6% 6.6% 6.1% 5.5% 5.7% 9.7% 5.9% 5.7% 4.8% AZ NM KS AR TN NC SC DC 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% 5.2% 6.6% 4.9% 7.5% OK LA MS AL GA 26.8% 22.4% 21.9% 22.1% 21.6% 11.3% 14.8% 12.7% 11.8% 11.6% 11.3% 5.7% 7.5% TX | ŀ | 6.3% CA | 5.4% | 6.8% CO | 8.6% | 4.7% MO | 5.8% | 5.6% | 4.9% | 5./% MD | 7.6% | 5.8% | | |
| 13.7% 11.1% 14.2% 13.0% 12.0% 12.7% 16.2% 13.7% 12.3% 13.7% 5.0% 4.6% 6.6% 6.1% 5.5% 5.7% 9.7% 5.9% 5.7% 4.8% AZ NM KS AR TN NC SC DC 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% 5.2% 6.6% 4.9% 7.5% 0K LA MS AL GA GA 7.5% 0K LA MS AL GA 7.5% 7.5% 0K LA MS AL GA 7.5% 7.5% 14.8% 12.7% 11.8% 11.6% 11.3% 7.5% 7.5% TX TX Y 23.8% 23.8% 25.3% 10.0% | | 23.2% | 20.5% | 23.4% | 25.0% | 20.8% | 22.5% | 26.9% | 22.8% | 24.0% | 21.0% | | | |
| 5.0% 4.6% 6.6% 6.1% 5.5% 5.7% 9.7% 5.9% 5.7% 4.8% AZ NM KS AR TN NC SC DC 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% 5.2% 6.6% 4.9% 7.5% OK LA MS AL GA 26.8% 22.4% 21.9% 22.1% 21.6% 11.3% 14.8% 12.7% 11.8% 11.6% 11.3% 11.6% 14.8% 12.7% 11.8% 11.6% 11.3% 11.6% 14.8% 12.7% 11.8% 11.6% 5.7% 7.5% TX TX FL PR 13.4% 11.3% 11.3% 10.0% | | 13.7% | 11.1% | 14.2% | 13.0% | 12.0% | 12.7% | 16.2% | 13.7% | 12.3% | 13.7% | | | |
| AZ NM KS AR TN NC SC DC 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% 5.2% 6.6% 4.9% 7.5% OK LA MS AL GA GA 26.8% 22.4% 21.9% 22.1% 21.6% 14.8% 12.7% 11.8% 11.6% 11.3% 6.9% 6.5% 4.7% 4.5% 5.7% TX FL PR 19.5% 11.3% 13.4% 10.0% | | 5.0% | 4.6% | 6.6% | 6.1% | 5.5% | 5.7% | 9.7% | 5.9% | 5.7% | 4.8% | | | |
| 23.2% 28.9% 22.2% 22.9% 21.6% 22.5% 20.7% 31.9% 14.9% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% 5.2% 6.6% 4.9% 7.5% OK LA MS AL GA 26.8% 22.4% 21.9% 22.1% 21.6% 14.8% 12.7% 11.8% 11.6% 11.3% 6.9% 6.5% 4.7% 4.5% 5.7% FL PR 19.5% 11.3% 13.4% 10.0% | | | AZ | NM | KS | AR | TN | NC | SC | DC | | | | |
| 14.5% 18.8% 12.3% 12.2% 11.1% 13.1% 12.4% 15.5% 5.2% 9.3% 5.1% 5.2% 5.2% 6.6% 4.9% 7.5% OK LA MS AL GA 26.8% 22.4% 21.9% 22.1% 21.6% 14.8% 12.7% 11.8% 11.6% 11.3% 6.9% 6.5% 4.7% 4.5% 5.7% FL PR 19.5% 11.3% 13.4% 10.0% | | | 23.2% | 28.9% | 22.2% | 22.9% | 21.6% | 22.5% | 20.7% | 31.9% | | | | |
| OK LA MS AL GA 26.8% 22.4% 21.9% 22.1% 21.6% 14.8% 12.7% 11.8% 11.6% 11.3% 6.9% 6.5% 4.7% 4.5% 5.7% TX FL 19.5% 11.3% 11.3% 13.4% 10.0% | | | 5.2% | 18.8% | 12.3% 5.1% | 5.2% | 5.2% | 13.1% 6.6% | 12.4% | 15.5% 7.5% | | | | |
| 26.8% 22.4% 21.9% 22.1% 21.6% 14.8% 12.7% 11.8% 11.6% 11.3% 6.9% 6.5% 4.7% 4.5% 5.7% TX FL PR 19.5% 13.4% 10.0% | | | J.Z 70 | 9.5% | 0K | <u> </u> | MS | AL | 4.9% | 7.5% | | | | |
| 14.8% 12.7% 11.8% 11.6% 11.3% 6.9% 6.5% 4.7% 4.5% 5.7% TX 19.5% 5.7% 11.3% 11.3% 11.3% 11.3% 10.0% | | | | | 26.8% | 22.4% | 21.9% | 22.1% | 21.6% | | | | | |
| 6.9% 6.5% 4.7% 4.5% 5.7% TX FL PR 19.5% 23.8% 25.3% 11.3% 13.4% 10.0% | | | | | 14.8% | 12.7% | 11.8% | 11.6% | 11.3% | | | | | |
| TX FL PR 19.5% 23.8% 25.3% 11.3% 13.4% 10.0% | _ | | | | 6.9% | 6.5% | 4.7% | 4.5% | 5.7% | | | | | |
| 19.5% 23.8% 25.3% 11.3% 13.4% 10.0% | | | | | TX | | | | | FL | | PR | | |
| | | | | | 19.5% | | | | | 23.8% | | 25.3% | | |
| | | | | | 11.3% | | | | | 13.4% | | 10.0% | | |

Source: <u>CDC</u>, <u>CDC</u>, TrendMacro calculations



Source: Covid Tracking Project, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

Recommended reading

U.K. Approves Study That Will Deliberately Infect Volunteers With Coronavirus

Benjamin Mueller New York Times February 17, 2021

Why Cuomo Should Be Worried About a Federal Probe

John B. Daukas *Wall Street Journal* February 21, 2021

Art Mystery Solved: Who Wrote on Edvard Munch's

'The Scream'?

Nina Siegal *New York Times* February 21, 2021

Meme of day

Dr. Moncef Slaoui calls out Biden for claiming COVID vaccine distribution as his administration's own

Angelica Stabile *Fox News* February 17, 2021

<u>Pfizer-BioNTech Shot Stops Covid's Spread, Israeli</u> <u>Study Shows</u>

Naomi Kresge and Jason Gale *Bloomberg* February 21, 2021



Source: Our beloved clients, and Power Line blog "The Week in Pictures"



The coronavirus <u>case</u> accelerometer... tracking the world's infection curves Share of infected population from first day with 100 confirmed cases, log scale



The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality*



Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Covid Tracking Project, TrendMacro calculations

Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Covid Tracking Project, TrendMacro calculations



Source: Covid Tracking Project,, TrendMacro calculations



The sun-belt hot-spot states (other than Texas)

Source: Covid Tracking Project,, TrendMacro calculations



Patient zero... and then everyone else











Source: Johns Hopkins, TrendMacro calculations

Impact in other hot-spots







